Ship Healthcare Holdings, Inc.

DB:5EZ Stock Report

Market Cap: €1.2b

Ship Healthcare Holdings Valuation

Is 5EZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5EZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 5EZ (€12.2) is trading below our estimate of fair value (€19.34)

Significantly Below Fair Value: 5EZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5EZ?

Key metric: As 5EZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 5EZ. This is calculated by dividing 5EZ's market cap by their current earnings.
What is 5EZ's PE Ratio?
PE Ratio12.5x
EarningsJP¥15.64b
Market CapJP¥194.97b

Price to Earnings Ratio vs Peers

How does 5EZ's PE Ratio compare to its peers?

The above table shows the PE ratio for 5EZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.6x
ILM1 Medios
28.5x47.8%€374.5m
HAEK HAEMATO
7.1xn/a€68.0m
RHK RHÖN-KLINIKUM
18.8x7.5%€843.4m
NXU Nexus
44.1x17.1%€1.2b
5EZ Ship Healthcare Holdings
12.5x7.7%€195.0b

Price-To-Earnings vs Peers: 5EZ is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (24.9x).

Price to Earnings Ratio vs Industry

How does 5EZ's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
5EZ 12.5xIndustry Avg. 17.7xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 5EZ is good value based on its Price-To-Earnings Ratio (12.5x) compared to the European Healthcare industry average (17.7x).

Price to Earnings Ratio vs Fair Ratio

What is 5EZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5EZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.5x
Fair PE Ratio18x

Price-To-Earnings vs Fair Ratio: 5EZ is good value based on its Price-To-Earnings Ratio (12.5x) compared to the estimated Fair Price-To-Earnings Ratio (18x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5EZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€12.20
€17.85
+46.3%
12.5%€19.70€14.07n/a4
Nov ’25€13.40
€18.07
+34.9%
12.5%€19.95€14.25n/a4
Oct ’25€14.30
€18.07
+26.4%
12.5%€19.95€14.25n/a4
Sep ’25€13.20
€18.07
+36.9%
12.5%€19.95€14.25n/a4
Aug ’25€13.40
€17.25
+28.7%
13.5%€20.03€13.55n/a4
Jul ’25€13.50
€17.25
+27.8%
13.5%€20.03€13.55n/a4
Jun ’25€13.20
€17.03
+29.0%
13.6%€19.93€13.48n/a4
May ’25€13.60
€17.13
+26.0%
12.3%€19.90€14.30n/a4
Apr ’25€12.60
€17.13
+36.0%
12.3%€19.90€14.30n/a4
Mar ’25€13.20
€16.62
+25.9%
12.0%€19.57€14.07n/a4
Feb ’25€14.00
€16.70
+19.3%
9.6%€18.78€14.40n/a4
Jan ’25€15.20
€16.70
+9.9%
9.6%€18.78€14.40n/a4
Dec ’24€13.00
€16.70
+28.5%
9.6%€18.78€14.40n/a4
Nov ’24€14.50
€17.58
+21.3%
5.8%€19.00€16.65€13.403
Oct ’24€14.20
€16.76
+18.0%
1.1%€17.01€16.57€14.303
Sep ’24€15.40
€16.76
+8.8%
1.1%€17.01€16.57€13.203
Aug ’24€14.50
€17.14
+18.2%
1.5%€17.51€16.93€13.403
Jul ’24€14.90
€18.64
+25.1%
9.8%€21.77€17.38€13.504
Jun ’24€15.70
€19.68
+25.3%
9.2%€21.74€17.35€13.203
May ’24€15.90
€20.85
+31.1%
8.7%€23.25€18.20€13.604
Apr ’24€16.60
€20.85
+25.6%
8.7%€23.25€18.20€12.604
Mar ’24€16.30
€20.85
+27.9%
8.7%€23.25€18.20€13.204
Feb ’24€17.40
€20.42
+17.4%
6.9%€22.50€18.58€14.004
Jan ’24€18.70
€20.42
+9.2%
6.9%€22.50€18.58€15.204
Dec ’23€18.90
€19.90
+5.3%
4.5%€21.13€18.58€13.004
Nov ’23€19.10
€19.45
+1.8%
5.9%€20.83€17.64€14.504

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$112.8m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$6.45

7D

4.0%

1Y

251.1%

Shandong Weigao Group Medical Polymer

HK$21.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.55

7D

-13.5%

1Y

-39.1%

CVS Health

US$68.3b

Provides health solutions in the United States.

CVS

US$52.20

7D

-2.4%

1Y

-16.6%